Operator: We also have a question from [indiscernible] with Leerink Partners.
Unidentified Analyst: This is [indiscernible]. Thanks for taking our questions. Maybe first off, on your RSV program, which 323 doses are you planning to evaluate in the upcoming challenge study? I don’t know if you have mentioned that? And maybe also, I guess what learnings from the development of 938 so far. Could you apply to possible future development of 323? And are you planning to go after similar patient populations for 323 or could you explore other populations as well?
Jay Luly: Yes, so, we haven’t disclosed the final doses for that study. We are likely to do that in connection with the announcement of the initiation of the study. So stay tuned for that. Again, we are aiming for early Q4. But suffice it to say there will be doses within the ranges that we have studied. We are really trying to just figure out what optimal doses for various exposures that we want to try to hit and look at the product profile overall. And then with regards to 938, I mean, we have learned a lot about RSV through the use of 938, and I can only imagine that we will have a more targeted expedient pathway for 323, based on our learnings, whether it was what we learned in the standard risk patient population, which is, that patient population doesn’t need a drug.
And then through the recruitment of our three high risk patient populations, there is very interesting teachings in each of those patient populations that you can only sort of figure out once you get into them. And we have learned a lot along the way with 938. So, exactly the trial after the human challenge study that is something that we are thinking about, very diligently right now, but not ready to speak to today.
Unidentified Analyst: And also are you planning to pursue or evaluate 323 in similar patient populations or would you explore other types of patients as well?
Jay Luly: Well, those are the three high risk patient populations. PEDs probably the largest patient population from a market perspective. High risk adults and immune compromised patients of different flavors. I mean, we have chosen from immune compromise, we at least in RSVTx with 938, we have zeroed in on hematopoetic stem cell transplant, but there is other immune patient populations, immune suppressed patient populations that one could also consider. But anyway, you want to be in a high risk patient population of one flavor or another if you really want to get it over the finish line.
Operator: And I’m showing no further questions at this time. I would like to turn the call back over to Jennifer Viera for any closing remarks.
Jennifer Viera: Thank you, operator and thanks to everyone for joining us today. If you have additional questions, please feel free to contact us by email or call us at the office. Thanks so much and have a good night.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.
